Quantitative Systematic Strategies LLC Avadel Pharmaceuticals PLC Transaction History

Quantitative Systematic Strategies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 09, 2021	SELL	$5.03 - $7.95 $138,978 - $219,658	-27,630 Closed	0 $0
Q3 2020 Nov 09, 2020	BUY	$5.02 - $8.98 $2,178 - $3,897	434 Added 1.6%	27,630 $139,000
Q2 2020 Aug 04, 2020	BUY	$7.25 - $11.75 $197,171 - $319,553	27,196 New	27,196 $220,000
Q4 2018 Feb 12, 2019	SELL	$1.74 - $4.66 $22,593 - $60,510	-12,985 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$4.08 - $7.14 $50,167 - $87,793	-12,296 Reduced 48.64%	12,985 $57,000
Q2 2018 Aug 07, 2018	BUY	$5.89 - $7.78 $74,573 - $98,502	12,661 Added 100.32%	25,281 $155,000
Q1 2018 May 04, 2018	BUY	$6.76 - $11.7 $85,311 - $147,654	12,620 New	12,620 $92,000

7.03M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $793M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Quantitative Systematic Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on Quantitative Systematic Strategies LLC with notifications on news.